Eli Lilly (LLY) EPS (Weighted Average and Diluted) (2012 - 2026)
Eli Lilly (LLY) reported EPS (Weighted Average and Diluted) of $8.26 for Q1 2026, up 169.93% on a YoY basis from $3.06 in Q1 2025, and up 11.77% quarter-over-quarter from $7.39 in Q4 2025.
Eli Lilly (LLY) EPS (Weighted Average and Diluted) (2012 - 2026) Analysis & Trends
Eli Lilly has reported EPS (Weighted Average and Diluted) for 15 years, with the latest figure at $8.26 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 169.93% year-over-year to $8.26; the trailing twelve-month figure through Mar 2026 stood at $28.15 (up 129.05% YoY), and the FY2025 full-year result was $22.95, up 95.99% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $8.26, up from $7.39 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $8.26 in Q1 2026, with the low at -$0.06 in Q3 2023.
- Historically, EPS (Weighted Average and Diluted) has averaged $3.27 across 5 years, with a median of $2.42 in 2023.
- Annual changes were most pronounced in 2023 — EPS (Weighted Average and Diluted) plunged 103.73% — and 2024, when it surged 1883.33%.
- Eli Lilly's EPS (Weighted Average and Diluted) stood at $2.14 in 2022, then gained by 13.08% to $2.42 in 2023, then jumped by 101.65% to $4.88 in 2024, then soared by 51.43% to $7.39 in 2025, then rose by 11.77% to $8.26 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $8.26 (Q1 2026), $7.39 (Q4 2025), and $6.21 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 8.26 |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 2.14 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 0.39 |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | -1.72 |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 3.34 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 1.61 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 0.47 |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 1.31 |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.26 |
| Dec 31, 2025 | 7.39 |
| Sep 30, 2025 | 6.21 |
| Jun 30, 2025 | 6.29 |
| Mar 31, 2025 | 3.06 |
| Dec 31, 2024 | 4.88 |
| Sep 30, 2024 | 1.07 |
| Jun 30, 2024 | 3.28 |
| Mar 31, 2024 | 2.48 |
| Dec 31, 2023 | 2.42 |
| Sep 30, 2023 | -0.06 |
| Jun 30, 2023 | 1.95 |
| Mar 31, 2023 | 1.49 |
| Dec 31, 2022 | 2.14 |
| Sep 30, 2022 | 1.61 |
| Jun 30, 2022 | 1.05 |
| Mar 31, 2022 | 2.10 |
| Dec 31, 2021 | 1.89 |
| Sep 30, 2021 | 1.22 |
| Jun 30, 2021 | 1.53 |